The global ABSSSI Market is estimated to be valued at US$ 3674.6 Mn or Billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are common bacterial infections that infect the skin and underlying tissues. These infections typically occur after minor cuts or burns. ABSSSI need to be treated with antibiotics to prevent further complications.

Market key trends:
One of the key trends in the ABSSSI market is the rising prevalence of antibiotic resistance. Many commonly used antibiotics are becoming less effective against ABSSSI causing pathogens due to overprescribing and misuse of antibiotics. This is prompting drugmakers to develop novel antibiotics with new mechanisms of action to overcome antibiotic resistance. However, developing new antibiotics is a complex and lengthy process.
SWOT Analysis

Strength: Acute Bacterial Skin And Skin Structure Infections (ABSSSI) drugs effectively treat infections caused by bacteria. They provide relief to patients suffering from skin infections.

Weakness: Development of drug resistance is a major challenge for ABSSSI drugs. Overuse and misuse can lead to bacteria developing resistance to available antibiotic treatments over time.

Opportunity: Rising prevalence of skin infections globally due to factors like increased outdoor activities, injuries, and poor hygiene presents an opportunity for ABSSSI drug manufacturers. Developing novel drugs with improved efficacy and reduced resistance is another opportunity area.

Threats: Stringent regulatory approvals and lengthy drug development process adds to the costs and acts as a threat. Patent expiries of major drugs also increases competition from generic versions.


Key Takeaways :

The global Acute Bacterial Skin And Skin Structure Infections Market is expected to witness high growth, exhibiting CAGR of 6.0% over the forecast period, due to increasing prevalence of skin infections driven by outdoor sports and recreational activities, injuries and reduced immunity.

North America dominates the global market and is expected to continue its dominance over the forecast period owing to rigorous clinical research and advanced healthcare facilities in the region. However, Asia Pacific is anticipated to exhibit fastest growth attributed to rising medical tourism, growing middle class population and increasing healthcare spending in the region.

Key players operating in the Acute Bacterial Skin And Skin Structure Infections are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. Major players are focused on developing new treatments to overcome antibiotic resistance.

Read More: https://www.blogger.com/u/0/blog/post/preview/2301919868420416273/6506713171308355401